Arabic Arabic English English French French German German
dark

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

Immix Biopharma, Inc. today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

40% of eligible population have had boosters; 28 community cases; 2 deaths; 31 people in hospital; two in ICU

Next Post

The unexpected benefits of fat in type 2 diabetes

Related Posts
Total
0
Share